About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 672 record(s)
Req # A-2022-000743
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-104567-43.Organization: Health Canada
February 2023
Req # A-2022-000818
Adverse Drug Reactions (ADRs). Report numbers: E2B_05427218, E2B_05478143, 00997810, 000995390, E2B_05469568, 000997770, 000998905, 000999775, 000985722.Organization: Health Canada
February 2023
Req # A-2022-001006
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_05672052, E2B_05635847, E2B_05627995, 001012252. ADRs for Pantoprazole sodium. Report numbers: E2B_05687063, E2B_05694473, E2B_05628332, E2B_05612082, E2B_05660986, E2B_05678047.Organization: Health Canada
February 2023
Req # A-2022-001050
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-109293-438.Organization: Health Canada
February 2023
Req # A-2022-001054
Adverse Drug Reaction (ADR). Report number: E2B_04238483.Organization: Health Canada
February 2023
Req # A-2022-001064
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-105095-605.Organization: Health Canada
February 2023
Req # A-2022-001070
Adverse Drug Reactions (ADRs) for Alendronic Acid. Report numbers: 000716510, E2B 02034338, E2B 02039383, E2B 02043606, E2B 02048160, E2B 02052077, E2B 02058874, 000720911, E2B 01781006.Organization: Health Canada
February 2023
Req # A-2022-001072
Adverse Drug Reaction (ADR). Report number: E2B_05322214.Organization: Health Canada
February 2023
Req # A-2022-001080
Adverse Drug Reaction (ADR) for JINARC. Report number: 001008538. ADRs for REXULTI. Report numbers: 001006210, E2B_05645875, E2B_05646027, E2B_05702141. ADR for ARIPIPRAZOLE. Report number: 001006264. ADRs for ABILIFY. Report numbers:…Organization: Health Canada
February 2023
Req # A-2022-001081
Adverse Drug Reactions (ADRs) for CELEXA. Report numbers: 00979116, 00978656, E2B_05023024, 00982655, 00978530. ADRs for CLOPIXOL. Report numbers: E2B_04897492, E2B_04773927, E2B_05008311. ADR for TRINTELLIX. Report number: 00970777.Organization: Health Canada
February 2023